ClinicalTrials.gg
Not yet recruitingNCT07468656Updated Nov 18, 2026

SCLC Blood Collection Study

An observational study in Small-cell Lung Cancer, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Duke University · Observational

How we know

Updated Nov 18, 2026Start date movedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

The overall objective of this project is to prospectively collect blood samples from patients with small cell lung cancer (SCLC) who are initiating or receiving systemic therapy. These samples will then be analyzed through a variety of assays to better characterize SCLC treatment in the real-world setting. Studies may include, but are not limited to, the following: 1) predictors of response to treatment, 2) identification of predictive biomarkers for treatment-related toxicities, including but not limited to cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving tarlatamab or other T cell-engaging therapies, 3) characterization of the immune cell environment induced by systemic therapies, 4) identification of resistance mechanisms to treatment, and 5) development of potential translational correlates.

For participants receiving tarlatamab: The investigators will prospectively collect blood samples from patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.

For participants receiving other systemic therapies (Chemotherapy, Immune Checkpoint Inhibitors, Antibody-Drug Conjugates, and Future/Novel Treatments): The investigators will prospectively collect blood samples from patients on Cycle 1 Day 1, Cycle 2 Day 1 of treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.

02

Conditions studied

  • Small-cell Lung Cancer
03

In context

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

This study's planned enrollment of 100 is below the median of 137 across 144 observational studies indexed under Small Cell Lung Carcinoma.

Browse Small Cell Lung Carcinoma studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with small cell lung cancer (SCLC) who are eligible for treatment with tarlatamab or other systemic therapies

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented small cell lung cancer (SCLC, pure or inclusive or mixed histology)
  • Initiating or currently receiving any systemic therapy for SCLC, including but not limited to: platinum-based chemotherapy, , tarlatamab, antibody-drug conjugates, lurbinectedin, or other /novel agents
  • Appropriate candidate for treatment based on investigator discretion
  • Age > 18 years
  • Signed written including HIPAA according to institutional guidelines

Exclusion criteria

Exclusion Criteria:

  • Does not meet all inclusion criteria
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tarlatamab

    Participants receiving tarlatamab as part of their routine cancer care.

  • Other Systemic Therapies

    Participants receiving other systemic therapies as part of their routine cancer care. This category includes, but is not limited to: platinum-etoposide chemotherapy (with or without concurrent radiation), chemoimmunotherapy (e.g., carboplatin/etoposide/atezolizumab, platinum/etoposide/durvalumab), maintenance immunotherapy (e.g., atezolizumab, durvalumab), consolidation immunotherapy (e.g., durvalumab post-chemoradiation for limited stage), lurbinectedin, antibody-drug conjugates (e.g., ifinatamab deruxtecan, sacituzumab govitecan, or other ADCs), topotecan, and any other systemic agents used in the treatment of small cell lung cancer (SCLC).

06

What researchers measure

Primary outcomes

  1. Number of blood samples collected

    Number of blood samples collected to better characterize therapies in real-world setting

    Time frame: Through study completion, an average of 8 times (Day 1, Day 8, Day 15, Week 6, Week 12, Week 18, Week 24, Week 36)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 62 observational studies under Small Cell Lung Carcinoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 47. This study's planned 23 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 12, 2026
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Nov 18, 2026
Enrollment
25→100
Nov 18, 2026
Eligibility
2 inclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedPathologically documented small cell lung cancer (SCLC), pure or neuroendocrine tumorinclusive or mixed histology)
  • AddedInitiating or currently receiving any systemic therapy for SCLC, including but not limited to: platinum-based chemotherapy, immune checkpoint inhibitors, tarlatamab, antibody-drug conjugates, lurbinectedin, or other investigational/novel agents
  • EditedAppropriate candidate for treatment with tarlatamab based on investigator discretion
Nov 18, 2026
Interventions
Arms or interventions changed
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of blood samples collected to better characterize tarlatamab in real-world settingTime frame: Days 1, 8, and 15 of tarlatamab and after each interval scan for disease assessment → Through study completion, an average of 8 times (Day 1, Day 8, Day 15, Week 6, Week 12, Week 18, Week 24, Week 36)
Nov 18, 2026
Title
SCLC Tarlatamab Blood Collection Study
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 2026→Jan 2027
    Enrollment 25→100
    Eligibility 2 inclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedPathologically documented small cell lung cancer (SCLC), pure or neuroendocrine tumorinclusive or mixed histology)
    • AddedInitiating or currently receiving any systemic therapy for SCLC, including but not limited to: platinum-based chemotherapy, immune checkpoint inhibitors, tarlatamab, antibody-drug conjugates, lurbinectedin, or other investigational/novel agents
    • EditedAppropriate candidate for treatment with tarlatamab based on investigator discretion
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of blood samples collected to better characterize tarlatamab in real-world settingTime frame: Days 1, 8, and 15 of tarlatamab and after each interval scan for disease assessment → Through study completion, an average of 8 times (Day 1, Day 8, Day 15, Week 6, Week 12, Week 18, Week 24, Week 36)
    Interventions Arms or interventions changed
    Title SCLC Tarlatamab Blood Collection Study
    + 3 other changes: verification date, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07468656
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Laura Alder, MD
Contact
laura.alder@duke.edu
+1 919 862 5400
Laura Alder, MD
principal investigator · Duke Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion